Organization | Dentsply International

Dentsply International Report issue

For profit Phase 4

Founded: York Haven PA United States (1899)

Status: No NME R&D (1899)

Organization Overview

First Clinical Trial

2009

NCT00869427

First Marketed Drug

1948

epinephrine (levophed)

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Dentsply International | DENTSPLY PHARM | Dentsply Sirona Implants

Active Ingredients

Marketed Drugs (6)

epinephrine (levophed) (1948)

etidocaine (duranest) (1976)

levonordefrin (Neo-Cobefrine) (1988)

lidocaine (xylocaine) (1948)

mepivacaine (carbocaine) (1984)

prilocaine (citanest) (1965)

Drugs in Phase 4 Trials (4)

articaine (Septocaine) (1 trial)

lidocaine (xylocaine) (2 trials)

prilocaine (citanest) (1 trial)

vitamin c (1 trial)

Drugs in Other Trials (2)

denosumab (prolia) (1 trial)

hydroxyapatite silica (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Communicable Diseases (Phase 4)

Infections (Phase 4)

Periodontal Diseases (Phase 4)

Pulpitis (Phase 4)

Spinal Cord Injuries (Phase 4)

Urinary Tract Infections (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 5
# of Trial APIs: 6